nephrocystin-4 Activators
Nephrocystin-4 Activators are a diverse array of chemical compounds tailored to enhance the functional activity of nephrocystin-4 through specific cellular and biochemical pathways integral to its role. Compounds such as Forskolin, IBMX, Rolipram, and Vinpocetine elevate intracellular cAMP or cGMP levels, thereby augmenting PKA or PKG pathway activation. This sequence of events is pivotal as PKA and PKG are known to phosphorylate substrates that directly or indirectly enhance the functional capacity of nephrocystin-4, particularly in kidney cells. Moreover, PMA's role in activating PKC further underscores the complexity of the regulatory network, as PKC activation can lead to the modulation of cell morphology and motility, processes in which nephrocystin-4 is a critical player.
In parallel, compounds like Sildenafil and Zaprinast focus on inhibiting phosphodiesterase-5, sustaining cGMP levels, which may promote vasodilation and improve renal blood flow, indirectly affecting nephrocystin-4's function in kidney tissues. Additionally, analogs such as 8-Br-cAMP and 8-Br-cGMP serve as direct activators of PKA and PKG, further endorsing the role of these kinases in modulating nephrocystin-4's activity. Beyond the realm of cyclic nucleotides, Y-27632 inhibits ROCK, potentially altering cytoskeletal dynamics and cellular morphology, which are critical for nephrocystin-4's function. AICAR and GW 501516 trigger AMPK and PPARδ, respectively, pathways associated with energy homeostasis and fatty acid metabolism, which can also impinge upon the signaling milieu of nephrocystin-4, thereby enhancing its activity under various physiological conditions.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, increasing intracellular cAMP levels. Elevated cAMP activates PKA. PKA phosphorylation can influence the ciliary function and cellular processes where nephrocystin-4 is localized, thus enhancing its activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a nonspecific inhibitor of phosphodiesterases, leading to increased cAMP and cGMP by preventing their degradation. This potentiates PKA and PKG pathways, which may enhance the cellular functions where nephrocystin-4 is involved. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram, a selective phosphodiesterase-4 inhibitor, leads to an increase in cAMP levels in targeted cells, particularly in renal tissue. Boosted cAMP levels can enhance PKA-mediated signaling, thus potentially enhancing nephrocystin-4 activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a PKC activator that can modulate signaling pathways involved in cell morphology and motility, processes where nephrocystin-4 is implicated, thus potentially enhancing its activity. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits phosphodiesterases 5 and 6, increasing cGMP levels, which could lead to improved ciliary function by enhancing PKG pathway signaling in cells expressing nephrocystin-4. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine is a phosphodiesterase-1 inhibitor that raises cAMP and cGMP levels, potentially affecting the signaling pathways in renal cells where nephrocystin-4 is active, thereby enhancing its activity. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
8-Br-cAMP is a cAMP analog that activates PKA. PKA activation can influence the cellular processes and signaling pathways associated with nephrocystin-4, potentially enhancing its function in the kidney. | ||||||
8-Bromo-cGMP | 51116-01-9 | sc-200316 sc-200316A | 10 mg 50 mg | $104.00 $354.00 | 7 | |
8-Br-cGMP is a cGMP analog that activates PKG. Through PKG activation, it could indirectly enhance the activity of nephrocystin-4 by influencing ciliary function and associated cellular signaling. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor that can modulate cytoskeletal organization and cell morphology. These processes are relevant to the cellular locations where nephrocystin-4 is active, potentially enhancing its functional role. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR activates AMPK, which can regulate cellular energy homeostasis. AMPK activation could influence cellular processes where nephrocystin-4 plays a role, thus enhancing its activity, especially under metabolic stress conditions. | ||||||